Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial Subjects

NCT04949490 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04949490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04949490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Rollover Trial to Evaluate the Safety and Immunogenicity of One or Two Boosting Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 Trial Subjects, or Two Boosting Doses of Comirnaty in BNT162-04 Trial Subjects
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Completed
Start date
July 26, 2021
Completion date
September 16, 2022
Enrollment
137 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection